Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

The conversation is about finding a reputable place to buy Clascoterone in the US. An alternative treatment, pyrilutamide, is suggested as a strong and official option.

Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

Treatment options for female alopecia androgenetica, discussing the availability of spironolactone online in The Netherlands and other potential treatments like finasteride, minoxidil and RU58841.

Clascoterone is suggested as an alternative for those who experience side effects from finasteride and dutasteride. It is not widely available yet, but some users are obtaining it from compounding pharmacies or suppliers like Echemi.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.

The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.

A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.

Anagenica.com has poor customer service but delivers quality hair loss products like liposomal dutasteride. OP recommends ordering directly from Farmacia Tristiana for better service.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

Combining dutasteride and an aromatase inhibitor may increase testosterone levels significantly, potentially enhancing athletic performance but also posing health risks like elevated blood pressure and worsened cholesterol. The user is experimenting with dutasteride, anastrozole, minoxidil, and ketoconazole shampoo to manage hair loss and estradiol levels, while monitoring side effects and hormone levels.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

Pyrilutamide 0.9% (kx-826) is available for shipping to Europe from Amazon US and Koshinemall. Shipping costs and availability vary between the two shops.

The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user has tried various hair loss treatments, including topilutamide, alfatradiol, pyrilutamide, and topical spironolactone, but experienced headaches. They are inquiring about the availability and legality of clascoterone in Spain.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.